New Veeva Pulse findings show congresses and early-career experts have the strongest influence on patient outcomes PLEASANTON, Calif. , July 25, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV ) today revealed that targeted pre-launch scientific outreach maximizes medical affairs teams' impact on treatment adoption in the latest Veeva Pulse Field Trends Report . The analysis shows biopharmas investing in pre-launch scientific activities and prioritizing congresses gain 40% faster treatment adoption than those that invested less.
Early-career experts are also more open to digital engagement and four times more likely to start patients on a new treatment. Healthcare professionals (HCPs) are turning to biopharmas to help distill rapidly evolving scientific evidence around new innovative medicines and complex diseases. By focusing pre-launch activity around clinical guidelines, publications, and congresses with a new group of stakeholders, medical affairs teams can reach key HCPs to improve treatment decisions.
"Gone are the days when medical could just focus on the top-tier scientific thought leaders," said Angela Smart , director of global medical excellence and operations at ADVANZ PHARMA. "The range of stakeholders has broadened, and it's imperative to expand our engagement strategies beyond traditional experts." The latest analysis from Veeva Pulse finds that: Targeted pre-launch scientific activities speed treatment adoption: By engaging key experts at congresses, helping de.